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Background: The Hedgehog (Hh) signaling pathway is
critical for embryonic development and its deregulation
is implicated in a number of tumor types. The role of the
Hh signaling pathway, however, in the initiation and
growth of non-small cell lung cancer is largely unknown.
Here, we investigate the role of the Hh pathway tran-
scription factor, GLI1, in lung squamous cell carcinoma
(SCC) and as a potential therapeutic target for treatment
of lung SCC.
Methods: GLI1 expression in human SCC cell lines was
evaluated by quantitative PCR and Western Blot. siRNA
and shRNA of GLI1 in these cell lines were utilized in
vitro and in vivo to test the requirement of GLI1 in tumor
growth. Small molecule modulators of GLI1 were tested
for their therapeutic potential.
Results: GLI1 mRNA expression was signiﬁcantly
elevated in lung SCC compared to normal lung and
lung adenocarcinoma patient specimens in several
human genomic databases. Importantly, over-
expression of GLI1 was correlated with poor overall
survival in lung cancer patients. siRNA-mediated
knock down of GLI1 in SCC cell lines decreased the
expression of GLI1 target genes and caused a signiﬁ-
cant reduction in colony formation. Stable knock down
of GLI1 in SCC cell lines caused a signiﬁcant reduction
in growth of xenograft tumors indicating the critical
role of GLI1 in lung SCC progression. Inhibition or
activation of SMO, an upstream component of Hh
pathway, did not alter GLI1 expression level in lung
SCC cell lines. However, inhibition of PI3K/AKT and
MAPK signaling pathways down-regulated GLI1
expression, suggesting that GLI1 expression is depen-
dent on PI3K/AKT and MAPK pathway activity rather
than Hh ligand. Small molecule inhibition of PI3K/
mTOR pathway or GLI1 signiﬁcantly reduced GLI1
expression, proliferation, and clonogenicity in SCC cell
lines. Combinatorial inhibition of PI3K and GLI1 by
BKM120 and arsenic trioxide (ATO), respectively,
signiﬁcantly abrogated the in vivo growth SCC tumors
in mice and correlated with decreased tumor GLI1
expression.Conclusion: Our ﬁndings demonstrate that GLI1 is
essential for lung SCC tumor progression. Furthermore,
GLI1 expression in SCC is independent of Hh pathway
ligand action and dependent on MAPK and PI3K pathway
activity. Direct inhibition of GLI1 by repurposing ATO in
combination with a PI3K inhibitor may represent a novel
therapeutic strategy for lung SCC.Validation of L-Myc as a viable
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Background and Hypothesis: The paucity of molecu-
lar targets for small cell lung cancer (SCLC) chemo-
prevention and therapy is largely due to the poor
understanding of SCLC progression beyond the role of
RB and P53 mutations crucial for tumor initiation.
Ampliﬁcation of the Myc family of oncogenes is one of
the most frequent alterations in human SCLC ge-
nomes. However, the concept of inhibiting these fac-
tors to intervene in SCLC progression, despite its clear
value as a targeted therapy, has not been formally
tested in the autochthonous model. We tested the
hypothesis that L-Myc is a key determinant of SCLC
and its pathway as a viable target for therapeutics
and chemoprevention.
Methods and Results: Using comparative gene
expression analysis of pre-cancerous cells (preSC) and
tumor cells, both derived from the genetically engi-
neered mouse model (GEMM), we identiﬁed a gene set
speciﬁc to SCLC tumorigenic progression and found
that L-Myc is the most up-regulated gene in the mouse
model. Retroviral overexpression of L-Myc, mimicking
the gene ampliﬁcation, was sufﬁcient to cause the
tumorigenic progression of the L-Myc-expressing preSC
in culture or allograft experiment, while CRISPR-medi-
ated knockout of L-Myc blocked the long-term growth of
SCLC cells in culture. Comparison of L-Myc-preSC with
control (non-transformed) preSC revealed a speciﬁc
gene signature, and the pathway analysis of the signature
indicated signiﬁcant activation of several molecular
pathways, including epithelium-to-mesenchyme transi-
tion, downstream of L-Myc during tumor progression.
More signiﬁcantly, conditional deletion of L-Myc in
the GEMM dramatically reduced tumor burden in a
February 2016 Abstracts S29dose-dependent manner and signiﬁcantly extended
survival of the mice.
Conclusions: These results provide comprehensive evi-
dence for the oncogenic functions of L-Myc and further
support the concept of targeting the gene and its related
molecular pathways to intervene in SCLC. Additionally,
the new approaches demonstrated in this study will
facilitate functional analysis of numerous candidate
genes, increasing the likelihood of determining cancer-
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the world. There is a signiﬁcant need to develop new
strategies that provide effective treatment for lung can-
cer. Current study reports that targeting oncogenic
transcription factors could be a potential treatment
method for lung cancer. The E2F transcription factor
family members have been shown to be involved in
cancer development. The E2F members have been
divided into transcription activators (E2F1-E2F3) and
repressors (E2F4-E2F8). E2F8 with E2F7 has been
known to play an important physiologic role in embry-
onic development and cell cycle regulation by repressing
E2F1. We found that E2F8, an E2F transcription factor
family member, is overexpressed in lung cancer cell lines
and tumors from lung cancer patients compared with
normal lung cells and tissues, as determined by immu-
noblotting or immunoﬂuorescence staining in human
lung cancer cells and tissues from lung cancer patients.
Kaplan-Meier analysis of data from a public database
showed that aberrantly overexpressed E2F8 in patients
with lung cancer is associated with worse prognosis.
Depletion of E2F8 inhibited cell proliferation, colony
formation, invasion and tumor growth in vitro and in
vivo, while growth of normal cells was not affected by
the loss of E2F8. In addition, depletion of E2F8 induced
substantial DNA damage in cancer cells but not in
normal cells. Moreover, targeting E2F8 using its speciﬁc
siRNAs and morpholino-modiﬁed antisense dramatically
suppressed tumor growth in in vivo studies using mouse
models, including s.c. xenograft in nude mice, syngeneic
mouse lung cancer model, and a transgenic lung cancer
mouse model. To identify genes regulated by E2F8, we
performed microarray analyses using human lung cancer
cell lines (NCI-H1975, H441, and H520) and AffymetrixHuman Genome Arrays. Bioinformatical analyses
revealed that knockdown of E2F8 deregulated gene sets
involved in regulation of transcription, cancer progres-
sion, chromatin organization, regulation of immune
system, glutamate receptor signaling, and cell surface
receptor signaling. Further analysis of E2F8 binding
motif using chromatin immunoprecipitation (ChIP) as-
says combined with sequencing (ChIP-Seq) method, we
identiﬁed genome-wide distribution of 204 E2F8 binding
sites. From the microarray analysis and ChIP-Seq assay,
we identiﬁed the UHRF1 (ubiquitin-like PHD and RING
domain-containing 1), critical for DNA replication of
cancer cells, as one of the E2F8 target genes. In conclu-
sion, we report that E2F8 is overexpressed in lung can-
cer and is required for the growth of lung cancer cells.
The E2F8 knockdown signiﬁcantly perturbed genes
involved in the DNA replication pathway in cancer cells.
These ﬁndings provide evidence that E2F8 is a novel
therapeutic target for lung cancer treatment.Rare but poor prognosis of TERT
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The mutation in the promoter region of telomerase
reverse transcriptase (TERT) and telomere length
have been focused in various cancers. In present
study, the frequency and clinical characteristics of
TERT promoter mutation and telomere length were
studied in non-small cell lung cancers (NSCLC). TERT
promoter mutation and telomere length were analyzed
in 188 patients by using sequencing and real-time
PCR, respectively. The TERT promoter mutation rate
was 2.2% (4/188) of NSCLC and it was associated
with regional lymph node invasion (p < 0.001) and
poor differentiation (p ¼ 0.060). Telomere length was
not associated with TERT promoter mutation and it
divided into high and low groups by median value
(3.04). Telomere length was shorter in males (p ¼
0.058) and smokers (p ¼ 0.008). Survival analyses
showed a poor prognosis of NSCLC with TERT pro-
moter mutation (p < 0.001). Multivariate survival
analyses demonstrated that TERT promoter mutation
was associated with poor overall survival (p ¼ 0.045).
These data demonstrated TERT promoter mutation
was not frequent in NSCLC, however, it might have a
potential value for prognostic factor in NSCLC.
